308 related articles for article (PubMed ID: 38807856)
21. Uncovering the Cardiovascular Threat: A Comprehensive Examination of Liver Fibrosis and Subclinical Atherosclerosis in Non-alcoholic Fatty Liver Disease.
Sharma N; Chakole S; Wandile B
Cureus; 2023 Oct; 15(10):e46946. PubMed ID: 38021670
[TBL] [Abstract][Full Text] [Related]
22. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss.
Pouwels S; Sakran N; Graham Y; Leal A; Pintar T; Yang W; Kassir R; Singhal R; Mahawar K; Ramnarain D
BMC Endocr Disord; 2022 Mar; 22(1):63. PubMed ID: 35287643
[TBL] [Abstract][Full Text] [Related]
23. Ectopic fat, insulin resistance and non-alcoholic fatty liver disease.
Byrne CD
Proc Nutr Soc; 2013 Nov; 72(4):412-9. PubMed ID: 23668723
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes of non-alcoholic fatty liver disease: Polish-case control study.
Kempiński R; Łukawska A; Krzyżanowski F; Ślósarz D; Poniewierka E
Adv Clin Exp Med; 2019 Dec; 28(12):1615-1620. PubMed ID: 31025557
[TBL] [Abstract][Full Text] [Related]
25. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome.
Moore JB
Proc Nutr Soc; 2010 May; 69(2):211-20. PubMed ID: 20158939
[TBL] [Abstract][Full Text] [Related]
26. [Cardiovascular Risk in Patients with Non-alcoholic Fatty Liver Disease].
Kim HS; Cho YK
Korean J Gastroenterol; 2017 Jun; 69(6):333-340. PubMed ID: 28637101
[TBL] [Abstract][Full Text] [Related]
27. NAFLD and cardiovascular diseases: a clinical review.
Kasper P; Martin A; Lang S; Kütting F; Goeser T; Demir M; Steffen HM
Clin Res Cardiol; 2021 Jul; 110(7):921-937. PubMed ID: 32696080
[TBL] [Abstract][Full Text] [Related]
28. The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease.
Francque SM
Eur Cardiol; 2014 Jul; 9(1):10-15. PubMed ID: 30310479
[TBL] [Abstract][Full Text] [Related]
29. Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence.
Mazzolini G; Sowa JP; Atorrasagasti C; Kücükoglu Ö; Syn WK; Canbay A
Cells; 2020 Nov; 9(11):. PubMed ID: 33187255
[TBL] [Abstract][Full Text] [Related]
30. Non-alcoholic fatty liver disease and dyslipidemia: An update.
Katsiki N; Mikhailidis DP; Mantzoros CS
Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
[TBL] [Abstract][Full Text] [Related]
31. [Non-alcoholic fatty liver].
Tagle Arrospide M
Rev Gastroenterol Peru; 2003; 23(1):49-57. PubMed ID: 12768215
[TBL] [Abstract][Full Text] [Related]
32. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship.
Muzica CM; Sfarti C; Trifan A; Zenovia S; Cuciureanu T; Nastasa R; Huiban L; Cojocariu C; Singeap AM; Girleanu I; Chiriac S; Stanciu C
Can J Gastroenterol Hepatol; 2020; 2020():6638306. PubMed ID: 33425804
[TBL] [Abstract][Full Text] [Related]
33. Caspase-11 promotes high-fat diet-induced NAFLD by increasing glycolysis, OXPHOS, and pyroptosis in macrophages.
Drummer C; Saaoud F; Jhala NC; Cueto R; Sun Y; Xu K; Shao Y; Lu Y; Shen H; Yang L; Zhou Y; Yu J; Wu S; Snyder NW; Hu W; Zhuo J'; Zhong Y; Jiang X; Wang H; Yang X
Front Immunol; 2023; 14():1113883. PubMed ID: 36776889
[TBL] [Abstract][Full Text] [Related]
34. Modifiers of Liver-Related Manifestation in the Course of NAFLD.
Nasr P; Blomdahl J; Kechagias S; Ekstedt M
Curr Pharm Des; 2020; 26(10):1062-1078. PubMed ID: 32156227
[TBL] [Abstract][Full Text] [Related]
35. Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease.
Mishra A; Younossi ZM
J Clin Exp Hepatol; 2012 Jun; 2(2):135-44. PubMed ID: 25755422
[TBL] [Abstract][Full Text] [Related]
36. Non-alcoholic steatohepatitis in children.
Nanda K
Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
[TBL] [Abstract][Full Text] [Related]
37. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
[TBL] [Abstract][Full Text] [Related]
38. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk.
Muzurović E; Mikhailidis DP; Mantzoros C
Metabolism; 2021 Jun; 119():154770. PubMed ID: 33864798
[TBL] [Abstract][Full Text] [Related]
39. Non-invasive tools for liver steatosis and steatohepatitis predict incidence of diabetes, cardiovascular disease and mortality 20 years later: The ATTICA cohort study (2002-2022).
Kouvari M; Chrysohoou C; Damigou E; Barkas F; Kravvariti E; Liberopoulos E; Tsioufis C; Sfikakis PP; Pitsavos C; Panagiotakos D; Mantzoros CS;
Clin Nutr; 2024 Mar; 43(3):900-908. PubMed ID: 38387279
[TBL] [Abstract][Full Text] [Related]
40. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
Wang K; Wei Y; Xu R; Li Y; Mao C
Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
